Literature DB >> 12947224

Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation.

Laura L Carter1, Beatriz M Carreno.   

Abstract

The B7 family of ligands and receptors plays a critical role in the modulation of immune responses. The B7/cytotoxic T-lymphocyte antigen-4 (CTLA-4) and the more recently identified programmed death ligand/programmed death-1 (PD-L/PD-1) ligand/receptor pairs define pathways that function as rheostats of lymphocyte activation. Analysis of receptor and ligand expression patterns, as well as the phenotype of CTLA-4 or PD-1-deficient mice, strongly suggests that these pathways are nonredundant. Current data suggest that the B7/CTLA-4 pathway functions primarily to attenuate, limit, and/or terminate naïve T-cell activation in secondary lymphoid organs. The PD-L/PD-1 pathway, on the other hand, may primarily attenuate, limit, and/or terminate T-, B-, and myeloid cell activation/effector function at sites of inflammation in the periphery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947224     DOI: 10.1385/IR:28:1:49

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  51 in total

1.  CTLA-4 regulates induction of anergy in vivo.

Authors:  R J Greenwald; V A Boussiotis; R B Lorsbach; A K Abbas; A H Sharpe
Journal:  Immunity       Date:  2001-02       Impact factor: 31.745

Review 2.  Immune inhibitory receptors.

Authors:  J V Ravetch; L L Lanier
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

Review 3.  The right place at the right time: novel B7 family members regulate effector T cell responses.

Authors:  Linda Liang; William C Sha
Journal:  Curr Opin Immunol       Date:  2002-06       Impact factor: 7.486

4.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

5.  Molecular basis of T cell inactivation by CTLA-4.

Authors:  K M Lee; E Chuang; M Griffin; R Khattri; D K Hong; W Zhang; D Straus; L E Samelson; C B Thompson; J A Bluestone
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

6.  Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement.

Authors:  P S Linsley; J Bradshaw; J Greene; R Peach; K L Bennett; R S Mittler
Journal:  Immunity       Date:  1996-06       Impact factor: 31.745

7.  CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice.

Authors:  E A Tivol; S D Boyd; S McKeon; F Borriello; P Nickerson; T B Strom; A H Sharpe
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

8.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

Review 9.  CTLA-4: new insights into its biological function and use in tumor immunotherapy.

Authors:  Jackson G Egen; Michael S Kuhns; James P Allison
Journal:  Nat Immunol       Date:  2002-07       Impact factor: 25.606

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

View more
  9 in total

1.  Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin-like receptors.

Authors:  Gabriella Henel; Karnail Singh; Dapeng Cui; Sergey Pryshchep; Won-Woo Lee; Cornelia M Weyand; Jörg J Goronzy
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

Review 2.  Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners.

Authors:  Marcos W Steinberg; Jr-Wen Shui; Carl F Ware; Mitchell Kronenberg
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

Review 3.  Immunotherapy in gastrointestinal cancers.

Authors:  Patrick Grierson; Kian-Huat Lim; Manik Amin
Journal:  J Gastrointest Oncol       Date:  2017-06

Review 4.  Targeting mucosal immunity in the battle to develop a mastitis vaccine.

Authors:  Mini Bharathan; Isis K Mullarky
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-10-04       Impact factor: 2.673

5.  Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques.

Authors:  Jacob D Estes; Shari N Gordon; Ming Zeng; Ann M Chahroudi; Richard M Dunham; Silvija I Staprans; Cavan S Reilly; Guido Silvestri; Ashley T Haase
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

Review 6.  Therapeutic vaccine for lymphoma.

Authors:  Seung-Tae Lee; Sattva S Neelapu; Larry W Kwak
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

Review 7.  Immunotherapy in Merkel cell carcinoma: role of Avelumab.

Authors:  Amruth R Palla; Donald Doll
Journal:  Immunotargets Ther       Date:  2018-03-02

8.  Novel Immunomodulatory Proteins Generated via Directed Evolution of Variant IgSF Domains.

Authors:  Steven D Levin; Lawrence S Evans; Susan Bort; Erika Rickel; Katherine E Lewis; Rebecca P Wu; Joseph Hoover; Sean MacNeil; David La; Martin F Wolfson; Mark W Rixon; Stacey R Dillon; Michael G Kornacker; Ryan Swanson; Stanford L Peng
Journal:  Front Immunol       Date:  2020-01-21       Impact factor: 7.561

9.  Generation of molecular-targeting helix-loop-helix peptides for inhibition of the interaction between cytotoxic T-lymphocyte-associated protein 4 and B7 in the dog.

Authors:  Tharanga Mr Ramanayake Mudiyanselage; Daisuke Fujiwara; Masataka Michigami; Shunichi Watanabe; Zhengmao Ye; Atsuko Ueda; Ryoji Kanegi; Shingo Hatoya; Ikuo Fujii; Kikuya Sugiura
Journal:  J Vet Med Sci       Date:  2022-06-24       Impact factor: 1.105

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.